KR101021933B1 - 자기 보존 수성 약제학적 조성물 - Google Patents

자기 보존 수성 약제학적 조성물 Download PDF

Info

Publication number
KR101021933B1
KR101021933B1 KR1020097007721A KR20097007721A KR101021933B1 KR 101021933 B1 KR101021933 B1 KR 101021933B1 KR 1020097007721 A KR1020097007721 A KR 1020097007721A KR 20097007721 A KR20097007721 A KR 20097007721A KR 101021933 B1 KR101021933 B1 KR 101021933B1
Authority
KR
South Korea
Prior art keywords
composition
concentration
less
borate
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097007721A
Other languages
English (en)
Korean (ko)
Other versions
KR20090058567A (ko
Inventor
바그와티 피. 카브라
매수드 에이. 초환
엘. 웨인 슈나이더
웨슬리 웨신 한
Original Assignee
알콘 리서치, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101021933(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알콘 리서치, 리미티드 filed Critical 알콘 리서치, 리미티드
Publication of KR20090058567A publication Critical patent/KR20090058567A/ko
Application granted granted Critical
Publication of KR101021933B1 publication Critical patent/KR101021933B1/ko
Assigned to 노파르티스 아게 reassignment 노파르티스 아게 권리의 전부이전등록 Assignors: 알콘 리서치, 엘엘씨
Assigned to 알콘 리서치, 엘엘씨 reassignment 알콘 리서치, 엘엘씨 권리의 전부이전등록 Assignors: 알콘 리서치, 리미티드
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
KR1020097007721A 2006-09-21 2007-09-20 자기 보존 수성 약제학적 조성물 Expired - Fee Related KR101021933B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82652906P 2006-09-21 2006-09-21
US60/826,529 2006-09-21
US82741106P 2006-09-28 2006-09-28
US60/827,411 2006-09-28

Publications (2)

Publication Number Publication Date
KR20090058567A KR20090058567A (ko) 2009-06-09
KR101021933B1 true KR101021933B1 (ko) 2011-03-16

Family

ID=39156274

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097007721A Expired - Fee Related KR101021933B1 (ko) 2006-09-21 2007-09-20 자기 보존 수성 약제학적 조성물

Country Status (21)

Country Link
US (3) US8268299B2 (https=)
EP (1) EP2068822B2 (https=)
JP (2) JP4785970B2 (https=)
KR (1) KR101021933B1 (https=)
AR (1) AR062929A1 (https=)
AT (1) ATE531358T1 (https=)
AU (1) AU2007299727B2 (https=)
BR (1) BRPI0717067A2 (https=)
CA (1) CA2606370C (https=)
CL (1) CL2007002705A1 (https=)
CY (1) CY1112138T1 (https=)
DK (1) DK2068822T4 (https=)
ES (1) ES2374444T5 (https=)
MX (1) MX2009002221A (https=)
PL (1) PL2068822T5 (https=)
PT (1) PT2068822E (https=)
RU (1) RU2436568C2 (https=)
SI (1) SI2068822T2 (https=)
TW (1) TWI394564B (https=)
UY (1) UY30605A1 (https=)
WO (1) WO2008036847A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
KR101421519B1 (ko) 2006-09-28 2014-07-30 알콘 리서치, 리미티드 자기 보존 수성 약제학적 조성물
TW200904485A (en) * 2007-05-18 2009-02-01 Alcon Res Ltd Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions
ES2638771T3 (es) * 2008-03-17 2017-10-24 Novartis Ag Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
AU2009330517A1 (en) * 2008-12-22 2010-07-01 Alcon Research, Ltd. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
TWI618539B (zh) * 2009-12-15 2018-03-21 遠景生物製藥股份有限公司 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
TW201127423A (en) * 2009-12-17 2011-08-16 Alcon Res Ltd Ophthalmic solutions with improved disinfection profiles
KR101946790B1 (ko) 2011-03-04 2019-02-13 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
CA2828635C (en) * 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
JP6150510B2 (ja) * 2011-12-12 2017-06-21 ロート製薬株式会社 眼科用水性組成物
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
TW201417814A (zh) * 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd 包括瑞巴派特之醫藥組成物
US20150374820A1 (en) * 2013-02-15 2015-12-31 Senju Pharmaceutical Co., Ltd. Difluprednate emulsion composition containing zinc
CN105263476A (zh) 2013-03-13 2016-01-20 库尔制药开发公司 用于治疗炎症的免疫修饰性颗粒
EP3037094A1 (en) 2014-12-23 2016-06-29 Poifa Warszawa SA Ophthalmic pharmaceutical composition
EP3273953B1 (en) 2015-03-27 2019-01-02 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US10632202B2 (en) 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
WO2019123266A1 (en) 2017-12-20 2019-06-27 Novartis Ag Ophthalmic composition having a prostaglandin and a beta-blocker
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
WO2021222117A1 (en) 2020-04-27 2021-11-04 Ocular Therapeutix, Inc. Methods of treating allergic conjunctivitis
US20220031739A1 (en) * 2020-07-31 2022-02-03 Eye Therapies Llc Anti-viral compositions and methods of use thereof
EP4393510A4 (en) 2021-09-30 2025-08-06 Rohto Pharma OPHTHALMOLOGICAL COMPOSITION
EP4543456A1 (en) * 2022-06-27 2025-04-30 Zaklady Farmaceutyczne "Polpharma" Spolka Akcyjna Preservative-free ophthalmic composition comprising a prostaglandin analogue
KR20250034105A (ko) 2022-07-06 2025-03-10 로토 세이야쿠 가부시키가이샤 안과 조성물
EP4309644A1 (en) * 2022-07-22 2024-01-24 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Preservative-free ophthalmic composition comprising an antiglaucoma agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212420A1 (en) 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2084870B (en) 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5221664A (en) 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
EP0766970A3 (en) 1990-12-27 2000-02-23 Allergan, Inc Method and composition for disinfecting contact lenses
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
CA2132826C (en) * 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5320843A (en) 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (https=) 1993-11-12 1996-04-21 Ciba Geigy Ag
AU3070395A (en) 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US6024954A (en) 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
CA2211361A1 (en) 1995-03-20 1996-09-26 Unilever Plc Liquid cleansing formulations
US5683993A (en) 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) * 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
US6121315A (en) 1996-09-20 2000-09-19 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) * 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
PT948357E (pt) 1996-12-13 2002-10-31 Alcon Lab Inc Utilizacao de amino alcoois de baixo peso molecular em composicoes oftalmicas
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
DK0999825T3 (da) 1997-07-29 2004-02-09 Alcon Lab Inc Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
US6034043A (en) 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
HUP0302161A3 (en) 2000-11-29 2005-01-28 Novartis Ag Aqueous disinfecting systems
AR035509A1 (es) * 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP2004339104A (ja) * 2003-05-14 2004-12-02 Rohto Pharmaceut Co Ltd 溶液の安定化方法
DE602004020665D1 (de) 2003-12-09 2009-05-28 Alcon Inc Verwendung von bisaminen zur verstärkung der antimn
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
WO2005060933A1 (en) 2003-12-11 2005-07-07 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050214382A1 (en) * 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212420A1 (en) 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition

Also Published As

Publication number Publication date
DK2068822T3 (da) 2012-01-23
US8323630B2 (en) 2012-12-04
US20110195132A1 (en) 2011-08-11
EP2068822A2 (en) 2009-06-17
BRPI0717067A2 (pt) 2013-09-24
JP2011246476A (ja) 2011-12-08
TW200820962A (en) 2008-05-16
AR062929A1 (es) 2008-12-17
AU2007299727A1 (en) 2008-03-27
DK2068822T4 (da) 2022-10-31
JP2010504358A (ja) 2010-02-12
SI2068822T2 (sl) 2022-10-28
JP5411897B2 (ja) 2014-02-12
EP2068822B2 (en) 2022-07-27
EP2068822B1 (en) 2011-11-02
CL2007002705A1 (es) 2008-05-16
CA2606370C (en) 2012-03-27
SI2068822T1 (sl) 2012-02-29
WO2008036847A3 (en) 2008-05-29
CY1112138T1 (el) 2015-11-04
RU2436568C2 (ru) 2011-12-20
AU2007299727B2 (en) 2011-10-06
UY30605A1 (es) 2008-03-31
PL2068822T5 (pl) 2022-11-14
CA2606370A1 (en) 2008-03-21
ES2374444T3 (es) 2012-02-16
ATE531358T1 (de) 2011-11-15
ES2374444T5 (es) 2022-11-21
JP4785970B2 (ja) 2011-10-05
US20130053440A1 (en) 2013-02-28
US8268299B2 (en) 2012-09-18
PT2068822E (pt) 2012-01-10
US20080075790A1 (en) 2008-03-27
TWI394564B (zh) 2013-05-01
RU2009114849A (ru) 2010-10-27
KR20090058567A (ko) 2009-06-09
PL2068822T3 (pl) 2012-03-30
WO2008036847A2 (en) 2008-03-27
HK1126667A1 (en) 2009-09-11
AU2007299727A8 (en) 2009-04-09
MX2009002221A (es) 2009-03-13

Similar Documents

Publication Publication Date Title
KR101021933B1 (ko) 자기 보존 수성 약제학적 조성물
US8388941B2 (en) Self preserved aqueous pharmaceutical compositions
EP2722035A1 (en) Aqueous pharmaceutical compositions containing borate-polyol complexes
US20140294750A1 (en) Aqueous pharmaceutical compositions containing borate-polyol complexes
CN101516332B (zh) 自身防腐的水性药物组合物
US20100021561A1 (en) Self-preserved aqueous pharmaceutical compositions
HK1126667B (en) Self preserved aqueous pharmaceutical compositions
HK1126419B (en) Self-preserved aqueous pharmaceutical compositions
HK1145631B (en) Aqueous pharmaceutical compositions containing borate-polyol complexes

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20140221

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20150130

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20160218

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20170302

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20190227

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20200227

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230308

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230308